PDCD1 and hepatocellular carcinoma: More importantly, such findings indicate that, immune checkpoint antibody treatments, such as nivolumab (anti‐PD1 antibody) and ipilimumab (anti‐CTLA‐4 antibody),42 will bring more therapeutic benefit to the high‐risk HCC cases than to low‐risk counterparts, thus leading to superior outcomes.